Home Companies UCB Pharma S.A.

UCB Pharma S.A.

Allée de la Recherche, 60
1070 Brüssel
Belgium

About UCB

With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in three therapeutic areas - CNS, inflammation and oncology.

Read more about UCB

Advertisement

Digital membrane chromatography opens up new horizons in protein analysis

Digital membrane chromatography opens up new horizons in protein analysis

Robust glass columns for demanding MPLC applications

Robust glass columns for demanding MPLC applications

Advanced Bioprocess Data Management and Automation Platform

Advanced Bioprocess Data Management and Automation Platform

Product portfolio of UCB

Product portfolio

Show all

Advertisement

Advanced Virus Quantification for Real-Time Process Control

Advanced Virus Quantification for Real-Time Process Control

Maximum binding capacity in ion exchange chromatography

Maximum binding capacity in ion exchange chromatography

First CO₂ Incubator Shaker with Integrated 180°C Sterilization

First CO₂ Incubator Shaker with Integrated 180°C Sterilization

News about UCB

21-Oct-2016 | business & finance

Evotec and UCB sign multi-year CNS pharmacology agreement

Evotec AG announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Under the terms of the three-year agreement, ...

25-Feb-2016 | science

Major pharma companies sign up to groundbreaking Parkinson's consortium

Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and ...

11-Feb-2016 | science

UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration

Strategic collaboration to discover transformational therapies for neurodegenerative disease

30-Jul-2015 | research and development

UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

UCB announced that the two EMBODY™ Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet their primary clinical ...

07-Apr-2015 | business & finance

UCB to focus on core business in India

UCB to sell its established brands portfolio in India to Dr. Reddy’s for € 118 million

31-Mar-2015 | business & finance

UCB secures multimillion pound funding boost from UK Government

UCB announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing ...

13-Jan-2015 | research and development

Dermira and UCB announce start of Phase 3 program for CIMZIA® (certolizumab pegol) in psoriasis

Dermira, Inc. and UCB announced that the first patients have been dosed in the Phase 3 clinical program designed to evaluate the efficacy and safety of ...

10-Nov-2014 | business & finance

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million

UCB, Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, announced they have entered into a ...

24-Jul-2014 | research and development

Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam

UCB announced an important advance in its research and development pipeline with positive topline results from the latest Phase 3 study with brivaracetam. ...

29-Oct-2013 | research and development

Evotec achieves first milestones in multi-target deal with UCB

Evotec AG announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of ...

11-Jul-2013 | research and development

UCB gets access to rights for an antibody programme from WILEX for non-oncology indications

WILEX AG and UCB announced that UCB has acquired an antibody programme from WILEX’ preclinical portfolio originally obtained from UCB in 2009. UCB has the ...

07-Jan-2013 | research and development

Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD ...

04-Jan-2013 | research and development

Astellas and UCB announce approval of Cimzia in Japan for the treatment of rheumatoid arthritis

Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) ...

20-Sep-2012 | business & finance

UCB and Proteros expand successful protein x-ray crystallography collaboration

Collaboration aims to accelerate drug discovery for new therapies in central nervous system (CNS) disorders and immunology diseases

17-Sep-2012 | manufacturing

In line with its strategy, UCB expands its biotechnology base in Belgium

Opening of new pilot biotechnology plant in Belgium

Show more news about UCB

Advertisement

Gentle Counterflow Centrifugation for Superior Cell Processing Results

Gentle Counterflow Centrifugation for Superior Cell Processing Results

High-Performance Sterilizing-Grade Filtration for Solvents and Oily Formulations

High-Performance Sterilizing-Grade Filtration for Solvents and Oily Formulations

Microplate reading, made easy: flexible multi-mode microplate reader with simplified assay setup

Microplate reading, made easy: flexible multi-mode microplate reader with simplified assay setup

Here you will find UCB Pharma S.A.

© 1997-2026 LUMITOS AG, All rights reserved